Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1096/fj.202002512 http://scihub22266oqcxt.onion/10.1096/fj.202002512 33495994!7995142!33495994     free     free     free Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       FASEB+J 2021 ; 35 (2): e21245 Nephropedia Template TP {{tp|p=33495994|t=2021. Is lymphopenia different between SARS and COVID-19 patients?|pdf=|usr=}}{{33495994}} gab.com Text Is lymphopenia different between SARS and COVID-19 patients JO: FASEB J http://www.kidney.de/pget.php?&tw=1&pmid=33495994 #FOAvip Lymphopenia is commonly observed in SARS and COVID-19 patients although the lymphocyte count is not always below 0.8 x 10(9) /L in all the patients. It is suggested that lymphopenia serves as a useful predictor for prognosis in the patients. It is also hypothesized that lymphopenia is related to glucocorticoids and apoptosis. However, the ordering between lymphopenia and apoptosis appears different between SARS and COVID-19 patients, ie, lymphopenia is prior to apoptosis in SARS patients whereas apoptosis is prior to lymphopenia in COVID-19 patients. This paper attempts to figure out this contradiction through three players, lymphopenia, glucocorticoids, and apoptosis. Although the literature does not provide a solid explanation, the level of glucocorticoids could determine the ordering between lymphopenia and apoptosis because the administration of high doses of glucocorticoids could lead to lymphopenia whereas low doses of glucocorticoids could benefit patients. In the meantime, this paper raises several questions, which need to be answered in order to better understand the whole course of COVID-19. Twit Text FOAVip Is lymphopenia different between SARS and COVID-19 patients ????FASEB J http://www.kidney.de/pget.php?&tw=1&pmid=33495994 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33495994 #FOAvip English Wikipedia <ref>{{Cite pmid|33495994}}</ref> Is lymphopenia different between SARS and COVID-19 patients? #MMPMID33495994 Yan S; Wu G FASEB J 2021[Feb]; 35 (2): e21245 PMID33495994show ga Lymphopenia is commonly observed in SARS and COVID-19 patients although the lymphocyte count is not always below 0.8 x 10(9) /L in all the patients. It is suggested that lymphopenia serves as a useful predictor for prognosis in the patients. It is also hypothesized that lymphopenia is related to glucocorticoids and apoptosis. However, the ordering between lymphopenia and apoptosis appears different between SARS and COVID-19 patients, ie, lymphopenia is prior to apoptosis in SARS patients whereas apoptosis is prior to lymphopenia in COVID-19 patients. This paper attempts to figure out this contradiction through three players, lymphopenia, glucocorticoids, and apoptosis. Although the literature does not provide a solid explanation, the level of glucocorticoids could determine the ordering between lymphopenia and apoptosis because the administration of high doses of glucocorticoids could lead to lymphopenia whereas low doses of glucocorticoids could benefit patients. In the meantime, this paper raises several questions, which need to be answered in order to better understand the whole course of COVID-19. |*COVID-19 Drug Treatment[MESH] |*COVID-19/complications/metabolism[MESH] |*Glucocorticoids/adverse effects/therapeutic use[MESH] |*Lymphopenia/drug therapy/etiology/metabolism[MESH] |*Severe Acute Respiratory Syndrome/complications/drug therapy/metabolism[MESH] |Apoptosis/drug effects[MESH] |Humans[MESH] |SARS-CoV-2/*metabolism[MESH]Is lymphopenia different between SARS and COVID-19 patients?(epmc).pdf DeepDyve Pubget Overpricing